Evidence map›Paper›PMID 39963753›Full record

ArticleNeuro-oncology2025

Targeting PGE2 mediated senescent neuron improves tumor therapy.

Jianyi Zhao, Linshi Wu, Gang Cai, Dan Ou, Keman Liao, Jian Yang, Li Zhou, Renhua Huang, Shukai Lin, Xi Huang and 5 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Prostaglandin EEXCLI journal · 2025
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jianyi ZhaoShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Linshi WuDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Gang CaiShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Dan OuShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Keman LiaoShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Jian YangDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Li ZhouShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Renhua HuangDepartment of Radiation Oncology, Ren Ji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shukai LinDepartment of Neurosurgery, Sanya Central Hospital, The Third People's Hospital of Hainan Province, Hainan, China.
Xi HuangDepartment of Digestive Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Qi LvDepartment of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Juxiang ChenDepartment of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Lu CaoShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Jiayi ChenShanghai Key Laboratory of Proton-Therapy, Shanghai, China.
Yingying LinShanghai Key Laboratory of Proton-Therapy, Shanghai, China.ORCID 0000-0002-6935-5681

Funding

Beijing Science and Technology Innovation Medical Development Foundation KC2021-JX-0170-9Clinical Research of Shanghai Municipal Health Commission 20224Y0025National Key Research and Development Program of China 2022YFC2404602National Key Research and Development Program of China 2023ZD0502206National Natural Science Foundation of China 81772654National Natural Science Foundation of China 82002630National Natural Science Foundation of China 82273278National Natural Science Foundation of China 82373202National Natural Science Foundation of China 82373514Scientific and Technological Innovation Action Plan of Shanghai Science and Technology Committee 22Y31900103Shanghai Association for Science and Technology 201409003000Shanghai Hospital Development Center Foundation SHDC12023108Shanghai Science and Technology Innovation Action Plan 23Y41900100
6 · The paper itself

Abstract

backgroundRecent studies have highlighted bidirectional signaling between tumors and neurons; however, the interactions between tumors and neurons in response to radio-/chemotherapy remain obscure, which hampers the tumor treatment.

methodsGlioblastoma organoids (GBOs) and primary neuron coculture, targeted metabonomics, RNA pulldown, mass spectrum, co-immunoprecipitation, RNA-sequencing, transcript/protein validations, and multi-electrode arrays were performed to analyze neuron-tumor interaction in response to therapy. In vivo validations were conducted in orthotopic mouse models. Diagnostic and prognostic values were evaluated in serum, tissue microarray as well as The Cancer Genome Atlas (TCGA).

resultsGBOs recruited and induced pro-tumor-survival senescent neurons upon radiation/chemotherapeutic treatment. Targeted metabonomics revealed that significantly increased tumor-derived prostaglandin E2 (PGE2) induced neuronal senescence phenotype. Screening of enzymes involved in PGE2 synthesis identified prostaglandin E synthase 3 (PTGES3) as the key enzyme responsible for PGE2 upregulation. Biochemical studies revealed that irradiation or chemotherapeutic drug-triggered asparagine endopeptidase (AEP) specifically cleaved eukaryotic translation initiation factor 4A1 (eIF4A1) to produce truncated C-terminal eIF4A1 (teIF4A1-C), which dissociated from DEAD-box helicase 6 (DDX6) and recruited eIF4A3 and polyadenylate-binding protein nuclear 1 (PABPN1) to promote the mRNA stability of PTGES3. Elevated PGE2 reciprocally enhanced AEP expression. Inhibiting PGE2 or AEP reduced neuronal senescence and delayed tumor progression. Strikingly, single-cell analysis further showed that expressions of AEP/PTGES3/EIF4A1 in tumor cells were consistent with senescent neuronal cyclin-dependent kinase inhibitor 1A (CDKN1A) in high-neuronal-connectivity glioblastoma. The serum PGE2 concentration was elevated after radiation and higher in resistant glioblastoma patients. High expression of PTGES3 was associated with a poor prognosis.

conclusionsOur study revealed that the AEP/PGE2 feedback loop modulates tumor-induced neuronal senescence upon radio-/chemotherapy and highlights the therapeutic value to improve tumor therapy.

Indexed as

Brain NeoplasmsCellular SenescenceDinoprostoneGlioblastomaNeuronsAnimalsHumansMicePrognosisTumor Cells, CulturedXenograft Model Antitumor AssaysDinoprostoneneuronPGE2radio-/chemotherapysenescencetumor

Identifiers

PMID39963753
PMCPMC12309717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.